Feb 17, 2017 at 15:29 | Source: Moneycontrol.com
Biocon shares gained 2.6 percent to hit a record high of Rs 1,123 after the US health regulator USFDA has accepted pharma major Mylan's biologics licence application (BLA) for MYL-1401H, a proposed biosimilar Pegfilgrastim.
Feb 17, 2017 at 14:50 | Source: PTI
US health regulator USFDA hasaccepted pharma major Mylan's biologics licence application(BLA) for MYL-1401H, a proposed biosimilar Pegfilgrastim,Biocon and Mylan have said.
Feb 17, 2017 at 09:51 | Source: CNBC-TV18
Biocon Thursday announced the US Food and Drug Administration has accepted Mylans Biologics License Application (BLA) for biosimilar chemotherapy drug Pegfilgrastim for review. Sharing details on the development with CNBC-TV18 Biocon Chairperson and Managing Director Kiran Mazumdar Shaw said, "This is a very important acceptance."
Feb 11, 2017 at 10:16 | Source: Moneycontrol.com
The company on Friday said it plans to spend about USD 80 million in next two years as it prepares to take the lead biosimilar molecule bevacizumab into clinical trial.
Feb 10, 2017 at 16:28 | Source: CNBC-TV18
Global drug major Novartis has invested, expanded its research & development (R&D) capabilities in India. The global leader in biosimilars through its subsidiary Sandoz is assessing Indian market dynamics to launch its portfolio.
Feb 09, 2017 at 22:30 | Source: Moneycontrol.com
Aurobindo Pharma forayed into biosimilars with acquisition of four cell culture derived biosimilar products from Switzerland-based TL Biopharmaceutical AG. As part of the deal. TL will supply all the developmental data for four molecules and Aurobindo will develop and market these products globally.
Feb 09, 2017 at 22:04 | Source: PTI
Drug firm Aurobindo Pharma hasforayed into the biosimilar development space by acquiringfour cell culture derived products from Switzerland-based TLBiopharmaceutical AG.
Jan 25, 2017 at 11:02 | Source: CNBC-TV18
Attributing the strong show in Q3FY17 to robust performance in biologics, Biocon Chairperson and MD Kiran Mazumdar-Shaw told CNBC-TV18 that Biocon is well poised to be front-runner in biosimilars. The acceptance of biosimilar Trastuzumab by the USFDA is a huge milestone for Mylan and Biocon, she said.
Jan 12, 2017 at 09:44 | Source: Moneycontrol.com
Biocon shares touched a record high of Rs 1,049.50 on Thursday, up nearly 5 percent intraday after the US health regulator has accepted biosimilar application for its proposed cancer drug.
Jan 12, 2017 at 08:56 | Source: PTI
The proposed biosimilar trastuzumab is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace, the two companies said in a statement.